Pharmacovigilance Signal Detection Software: What to Look For in 2026
"Signal detection software" covers several genuinely different categories of tools that catch different things and miss different things. Buying the wrong category for your gap is a common and expensive mistake. Here is how they actually differ.
Three categories, three different jobs
Most PV teams already run one category — usually statistical disproportionality analysis on their own case database, as required under GVP Module IX. The gap that catches teams out is assuming that internal signal detection covers everything. It does not cover signals that a health authority has identified from sources you cannot see: aggregated case data across all marketing authorisation holders, epidemiological studies, or safety reviews triggered by another company's product in your class.
The three categories compared
1. Statistical disproportionality tools
Analyse your own case safety report (ICSR) database using methods like PRR, ROR, or EBGM to detect statistical signals within your own adverse event data. Core to internal signal detection under GVP Module IX.
What it catches
Statistical patterns in your own reported adverse events.
What it misses
Signals a health authority has already identified from population-level data, published guidance changes, or safety communications from other MAHs’ products in the same class.
2. Literature monitoring platforms
Continuously scan medical literature databases (Embase, PubMed) for publications mentioning your products or active substances, flagging potential safety signals in published case reports and studies.
What it catches
Emerging signals discussed in academic and clinical literature before they reach regulatory action.
What it misses
Regulatory agency actions and communications that have not yet been reflected in published literature.
3. Regulatory intelligence / agency monitoring
Continuously monitor health authority publications — PRAC recommendations, safety communications, recalls, RMP updates — and classify them by relevance and urgency. This is where a PRAC signal review, once finalised, first becomes visible outside the agency.
What it catches
Class-wide signals, safety communications, and recalls the moment a health authority publishes them — including signals detected by other companies’ pharmacovigilance systems that led to agency action.
What it misses
Signals still internal to a single company’s case database that have not yet reached a health authority.
Why regulatory-intelligence monitoring is the layer most teams are missing
Internal disproportionality analysis and literature monitoring are well established in most PV systems. What is less consistently covered: continuous monitoring of what health authorities themselves are publishing. When PRAC completes a signal assessment and recommends a label update, that decision is published as a regulatory communication — often before it shows up anywhere your literature monitoring tool would catch it, and independent of whatever your own case database shows.
NoxReg covers this layer specifically: continuous monitoring of 55+ global health authorities, with every update classified by importance and category so a PRAC recommendation, safety notice, or recall relevant to your products surfaces as an Urgent item — not something your team has to go find.
See what your team might be missing.
NoxReg monitors 55+ health authorities and flags safety signals the moment they are published. 14-day free trial, no credit card required.
Start free trial →